FDAapproval65% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: provides agency context on approval that may shape timing or evidence expectations for Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · ADC
- Sub-indication
- General
Related signal: Merck Acknowledges Daiichi Sankyo's ADC Manufacturing Update